ROBERT ALEXANDER INGRAM - 18 Jun 2021 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role: Director
Signature: /s/ Brent Hatzis-Schoch, as Attorney-in-Fact
Issuer symbol: BDTX
Transactions as of: 18 Jun 2021
Net transactions value: +$16,252
Form type: 4
Filing time: 22 Jun 2021, 18:13:47 UTC
Previous filing: 01 Jun 2021
Next filing: 02 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDTX	Common Stock	Award	$16,252	+1,255	+20%	$12.95	7,437	18 Jun 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BDTX	Stock Option (Right to Buy)	Award	$0	+15,000		$0.000000	15,000	18 Jun 2021	Common Stock	15,000	$12.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2	The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 17, 2021.
F3	This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.